Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
The differential diagnosis of clear cell, papillary, and chromophobe renal cell carcinoma is clinically important, because these tumor subtypes are associated with different pathobiology and clinical behavior. For cases in which histopathology is equivocal, immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction can assist in the differential diagnosis by measuring expression of subtype-specific biomarkers. Several renal tumor biomarkers have been discovered in expression microarray studies. However, due to heterogeneity of gene and protein expression, additional biomarkers are needed for reliable diagnostic classification. We developed novel bioinformatics systems to identify candidate renal tumor biomarkers from the microarray profiles of 45 clear cell, 16 papillary, and 10 chromophobe renal cell carcinomas; the microarray data was derived from 2 independent published studies. The ArrayWiki biocomputing system merged the microarray data sets into a single file, so gene expression could be analyzed from a larger number of tumors. The caCORRECT system removed non-random sources of error from the microarray data, and the omniBioMarker system analyzed data with several gene-ranking algorithms to identify algorithms effective at recognizing previously described renal tumor biomarkers. We predicted these algorithms would also be effective at identifying unknown biomarkers that could be verified by independent methods. We selected 6 novel candidate biomarkers from the omniBioMarker analysis and verified their differential expression in formalin-fixed paraffin-embedded tissues by quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. The candidate biomarkers were carbonic anhydrase IX, ceruloplasmin, schwannomin-interacting protein 1, E74-like factor 3, cytochrome c oxidase subunit 5a, and acetyl-CoA acetyltransferase 1. Quantitative reverse transcriptase-polymerase chain reaction was performed on 17 clear cell, 13 papillary and 7 chromophobe renal cell carcinoma. Carbonic anhydrase IX and ceruloplasmin were overexpressed in clear cell renal cell carcinoma; schwannomin-interacting protein 1 and E74-like factor 3 were overexpressed in papillary renal cell carcinoma; and cytochrome c oxidase subunit 5a and acetyl-CoA acetyltransferase 1 were overexpressed in chromophobe renal cell carcinoma. Immunohistochemistry was performed on tissue microarrays containing 66 clear cell, 16 papillary, and 12 chromophobe renal cell carcinomas. Cytoplasmic carbonic anhydrase IX staining was significantly associated with clear cell renal cell carcinoma. Strong cytoplasmic schwannomin-interacting protein 1 and cytochrome c oxidase subunit 5a staining were significantly more frequent in papillary and chromophobe renal cell carcinoma, respectively. In summary, we developed a novel process for identifying candidate renal tumor biomarkers from microarray data, and verifying differential expression in independent assays. The tumor biomarkers have potential utility as a multiplex expression panel for classifying renal cell carcinoma with equivocal histology. Biomarker expression assays are increasingly important for renal cell carcinoma diagnosis, as needle core biopsies become more common and different therapies for tumor subtypes continue to be developed.
Osunkoya
Adeboye O
AO
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Yin-Goen
Qiqin
Q
Phan
John H
JH
Moffitt
Richard A
RA
Stokes
Todd H
TH
Wang
May D
MD
Young
Andrew N
AN
D000465:Algorithms; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D019295:Computational Biology / Q000379:methods*; D003937:Diagnosis, Differential; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction
D014408:Biomarkers, Tumor
Eur J Cancer. 2005 Dec;41(18):2935-47
16310354
Oncogene. 2000 Apr 6;19(15):1941-9
10773884
Int J Cancer. 2008 Jul 15;123(2):395-400
18464292
Am J Surg Pathol. 2002 Apr;26(4):403-12
11914617
Nature. 2007 Feb 15;445(7129):691
17301755
Oncogene. 2002 May 30;21(24):3934-8
12032832
J Clin Oncol. 2002 May 1;20(9):2376-81
11981011
J Pathol. 2005 Feb;205(3):377-87
15682440
Conf Proc IEEE Eng Med Biol Soc. 2006;2006:3325-8
17947022
BMC Bioinformatics. 2008 May 28;9 Suppl 6:S18
18541053
Prostate. 2008 Jan 1;68(1):20-33
18000807
Nat Protoc. 2007;2(5):1152-65
17546006
J Biol Chem. 2001 Jun 15;276(24):20989-98
11399774
Am J Pathol. 2001 Feb;158(2):419-29
11159180
Cancer Lett. 1997 Dec 23;121(2):139-45
9570351
Genome Biol. 2007;8(1):102
17274839
J Mol Diagn. 2005 May;7(2):206-18
15858144
Brief Bioinform. 2006 Jun;7(2):166-77
16772260
Conf Proc IEEE Eng Med Biol Soc. 2006;2006:3317-20
17947020
Indian J Physiol Pharmacol. 2003 Jan;47(1):108-10
12708132
Clin Cancer Res. 2003 Feb;9(2):802-11
12576453
J Urol. 2006 Jun;175(6):2302-6
16697863
Biostatistics. 2003 Apr;4(2):249-64
12925520
Clin Cancer Res. 2005 Aug 15;11(16):5730-9
16115910
Oncogene. 1997 Nov 13;15(20):2449-62
9395241
Mol Cell Biol. 2000 Mar;20(5):1699-712
10669747
Oncogene. 2003 Oct 2;22(43):6810-8
14555994
Annu Int Conf IEEE Eng Med Biol Soc. 2007;2007:4633-6
18003038
BMC Evol Biol. 2008 Jan 15;8:8
18197981
Oncogene. 2000 Dec 18;19(55):6490-502
11175365
Ann Surg Oncol. 2004 Jan;11(1):71-7
14699037
J Trace Elem Med Biol. 2001;15(2-3):193-6
11787988
Am J Pathol. 2003 Mar;162(3):925-32
12598325
Genome Biol. 2003;4(4):R28
12702209
Clin Cancer Res. 2001 Jul;7(7):2145-51
11448934
Nat Biotechnol. 2008 Jan;26(1):83-90
18157119
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Hum Pathol. 2009 Feb;40(2):206-10
18799195
Proteomics. 2005 Aug;5(12):3205-13
16003825
Crit Rev Oncol Hematol. 2007 Aug;63(2):111-24
17555981
Oncogene. 2000 Jan 6;19(1):151-4
10644990
Indian J Physiol Pharmacol. 2004 Oct;48(4):486-8
15907060
Annu Rev Cell Dev Biol. 2006;22:129-57
16753029
Am J Surg Pathol. 2003 Feb;27(2):199-205
12548166
Am J Clin Pathol. 2005 Mar;123(3):421-9
15716239
Biochim Biophys Acta. 2008 Jan;1785(1):32-54
17980164
Br J Cancer. 2001 Nov 2;85(9):1372-82
11720477
Am J Surg Pathol. 2000 Sep;24(9):1247-56
10976699
Am J Surg Pathol. 2002 Mar;26(3):281-91
11859199
Clin Cancer Res. 2005 Sep 15;11(18):6558-66
16166433
Carcinogenesis. 2002 May;23(5):759-68
12016148
Eur Urol. 2008 Jun;53(6):1219-25
18082317
Am J Clin Pathol. 2004 Jun;121(6):878-83
15198361
Cancer Biol Ther. 2007 Jan;6(1):76-82
17172821
BJU Int. 2008 Jun;101 Suppl 4:25-30
18430119
Am J Pathol. 2001 May;158(5):1639-51
11337362
Ann Biomed Eng. 2007 Jun;35(6):1068-80
17458699
Int Urol Nephrol. 1997;29(4):427-32
9405999
Mol Cell Biol. 2004 Jun;24(12):5548-64
15169914
Turk J Gastroenterol. 2005 Jun;16(2):81-4
16252197
J Biol Chem. 2007 Jul 6;282(27):19820-30
17491012
Am J Surg Pathol. 2004 Jan;28(1):69-76
14707866